In this episode of Denatured, BioSpace editorial team members, Senior Editor, Annalee Armstrong, and News Editor, Dan Samorodnitsky, discuss their post-JPM takeaways and 2026 forecasts after speaking to a range of pharma and biotech executives and investors last week. Hosts<a href="https://www.linkedin.com/in/jennifersmithparker/" rel="noopener noreferrer nofollow" target="_blank">⁠</a><a href="https://www.linkedin.com/in/jennifersmithparker/" rel="noopener noreferrer nofollow" target="_blank">Jennifer Smith-Parker⁠</a>, Director of Insights, BioSpace<a href="https://www.linkedin.com/in/lorielliskatz/" rel="noopener noreferrer nofollow" target="_blank">⁠</a> Guests<a href="https://www.linkedin.com/in/annalee-armstrong/" rel="noopener noreferrer nofollow" target="_blank">⁠Annalee Armstrong, </a>Senior Editor, BioSpace<a href="https://www.linkedin.com/in/dan-samorodnitsky/" rel="noopener noreferrer nofollow" target="_blank">⁠Dan Samorodnitsky</a>, News Editor, BioSpace Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.

Roche Makes Obesity Splash, Moderna Cans Vaccine Trials, Sarepta’s New Data, More

Unravel the business of science with BioSpace. We dive into biopharma's top stories and biggest challenges, whether it’s layoffs, pipeline shake-ups, acquisitions, new FDA approvals or how to regulate AI in drug development.